Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Saved in:
| Title: | Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. |
|---|---|
| Authors: | Braess J; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany. Jan.Braess@barmherzige-regensburg.de.; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany. Jan.Braess@barmherzige-regensburg.de., Amler S; Insitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.; Friedrich Löffler Institute, Federal Research Centre, Greifswald-Insel Riems, Germany., Kreuzer KA; Department of Internal Medicine I, University Hospital, Cologne, Germany., Spiekermann K; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Lindemann HW; Department of Hematology and Oncology, Catholic Hospital, Hagen, Germany., Lengfelder E; Department of Medicine III, University Hospital, Mannheim, Germany., Graeven U; Department of Medicine I, Hospital Maria Hilf, Mönchengladbach, Germany., Staib P; Department of Hematology and Medical Oncology, St. Antonius Hospital, Eschweiler, Germany., Ludwig WD; Department of Hematology and Oncology and Tumor Immunology, Helios Hospital, Berlin-Buch, Germany., Biersack H; Department of Medicine I, University Hospital, Lübeck, Germany., Ko YD; Department of Medicine I, Johanniter Hospital, Bonn, Germany., Uppenkamp MJ; Department of Medicine A, Klinikum Ludwigshafen, Ludwigshafen, Germany., De Wit M; Department of Hematology, Oncology and Palliative Care, Vivantes Klinikum Neukölln, Berlin, Germany., Korsten S; Department of Medicine, Vinzenz Pallotti Hospital, Bergisch-Gladbach, Germany., Peceny R; Department of Hematology and Oncology, Klinikum Osnabrück, Osnabrück, Germany., Gaska T; Department of Hematology and Oncology, St. Josef Hospital, Paderborn, Germany., Schiel X; Department of Hematology and Oncology, Klinikum Harlaching, Munich, Germany., Behringer DM; Department of Hematology, Oncology and Palliative Care, Augusta Hospital, Bochum, Germany., Kiehl MG; Department of Medicine I, Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany., Zinngrebe B; Department of Hematology, Oncology and Palliative Care, Evangelisches Krankenhaus, Bielefeld, Germany., Meckenstock G; Department of Medical Oncology, Radiooncology, Hematology and Palliative Care, St. Josef Hospital, Gelsenkirchen, Germany., Roemer E; Department of Hematology and Oncology, Klinikum Idar-Oberstein, Idar-Oberstein, Germany., Medgenberg D; Department of Medicine III, Klinikum Leverkusen, Leverkusen, Germany., Spaeth-Schwalbe E; Department of Medicine, Vivantes Klinikum Spandau, Berlin, Germany., Massenkeil G; Department of Medicine II, Klinikum Gütersloh, Gütersloh, Germany., Hindahl H; Department of Medicine I, St. Johannes Hospital, Dortmund, Germany., Schwerdtfeger R; Department for Bone Marrow and Blood Stem Cell Transplantation, DKD Deutsche Klinik für Diagnostik, Wiesbaden, Germany., Trenn G; Department of Medicine I, Knappschaftskrankenhaus, Bottrop, Germany., Sauerland C; Insitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany., Koch R; Insitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany., Lablans M; Insitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany.; Division of Medical Informatics in Translational Oncology, DKFZ German Cancer Research Center, Heidelberg, Germany., Faldum A; Insitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany., Görlich D; Insitute for Biostatistics and Clinical Research, University Hospital, Münster, Germany., Bohlander SK; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.; Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand., Schneider S; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Dufour A; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Buske C; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany.; Institute of Experimental Cancer Research, University Hospital, Ulm, Germany., Fiegl M; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Subklewe M; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Braess B; Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany.; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Unterhalt M; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Baumgartner A; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany., Wörmann B; German Society of Hematology and Oncology DGHO, Berlin, Germany., Beelen D; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany., Hiddemann W; Department of Medicine III, University Hospital LMU Campus Grosshadern, Munich, Germany. |
| Corporate Authors: | AML-CG |
| Source: | Leukemia [Leukemia] 2018 Dec; Vol. 32 (12), pp. 2558-2571. Date of Electronic Publication: 2018 Oct 01. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
